Patient perspectives on fluticasone–vilanterol versus other corticosteroid combination products for the treatment of asthma

Conclusion: Individuals may have drug- and device-specific preferences that should be incorporated into therapeutic decision making. Limited data indicate that clinical and patient-oriented efficacy/safety outcomes of FF–VI are likely comparable to other available combinations for adults with asthma. Patient-friendly features include once-daily dosing, flexibility of dose timing, and design/ease of the use of the device. Additional larger and long-term comparative studies are needed to determine whether these features translate into greater efficacy, safety, patient preference, or adherence versus other ICS–LABA combinations. In the next few years, the availability of less expensive generic ICS–LABA products may strongly influence patient preference. Keywords: Breo, fluticasone–vilanterol, Ellipta®, patient preference, adherence, inhaled corticosteroid, respiratory devices, long acting beta receptor agonist
Source: Patient Preference and Adherence - Category: Global & Universal Tags: Patient Preference and Adherence Source Type: research